Dark

Check out our Dark Pool Levels

CWBR
COHBAR INC
stock OTC

Inactive

Jan 6, 2025

0.4100USD0.000%(0.0000)605

Pre-market

0.00USD-100.000%(-0.41)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 3, 2022

09:00AM EST CohBar to Present at H.C. Wainwright BIOCONNECT Conference GlobeNewswire Inc

Dec 17, 2021

09:00AM EST Founding board members transition to reconstituted Scientific Advisory Board GlobeNewswire Inc

Nov 29, 2021

09:00AM EST CohBars CEO to Participate in Upcoming BIO Webinar GlobeNewswire Inc

Nov 19, 2021

04:46PM EST 'Avoid CohBar: Red Flags And An Exorbitant Valuation' -Seeking Alpha Blog Post From Contributor Benzinga

Nov 15, 2021

04:18PM EST CohBar Q3 EPS $(0.05) Beats $(0.08) Estimate Benzinga

04:02PM EST CohBar Reports Third Quarter 2021 Financial Results and Provides GlobeNewswire Inc

11:07AM EST Earnings Scheduled For November 15, 2021 Benzinga

Nov 8, 2021

08:29AM EST The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Benzinga

Nov 1, 2021

09:00AM EDT CohBar to Announce 2021 Third Quarter Financial Results and GlobeNewswire Inc

Oct 28, 2021

02:45PM EDT Mid-Afternoon Market Update: Dow Surges 160 Points; Wolfspeed Shares Gain After Q1 Results Benzinga

12:16PM EDT Mid-Day Market Update: Nasdaq Rises Over 1%; Rafael Holdings Shares Slide Benzinga

08:46AM EDT CohBar Prices ~20.8M Share Offering At $0.72/Share Benzinga

08:45AM EDT CohBar Announces Pricing of $15.0 Million Public Offering of GlobeNewswire Inc

06:01AM EDT The following are some of the stocks making big moves in Thursday's pre-market trading (as of 05.45 A.M. EDT). RTTNews

Oct 27, 2021

04:02PM EDT CohBar Reports Offering Of Common Stock, Warrants, No Size Disclosed Benzinga

04:01PM EDT CohBar Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire Inc

Oct 13, 2021

01:38PM EDT CohBar Announces CB4211 Phase 1a/1b Results Selected For Late Breaker Presentation At The Liver Meeting 2021 Benzinga

09:00AM EDT CohBar Announces CB4211 Phase 1a/1b Results Selected for Late GlobeNewswire Inc

Oct 5, 2021

09:00AM EDT CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Dr. Joseph Sarret, will present a company overview at the H.C. Wainwright 5th Annual NASH Investor Conference, being held virtually on October 12, 2021. GlobeNewswire Inc

Sep 15, 2021

09:00AM EDT CohBar Appoints Joanne Yun, Ph.D. to Its Board of Directors GlobeNewswire Inc

Sep 8, 2021

09:06AM EDT CohBar Granted US Patent Covering CB4211 Compositions And Use For Treating Nonalcoholic Steatohepatitis Benzinga

09:00AM EDT CohBar Granted U.S. Patent Covering CB4211 Compositions and Use GlobeNewswire Inc

Sep 2, 2021

04:05PM EDT CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Dr. Joseph Sarret, will present a company overview at the following investor conferences in September. GlobeNewswire Inc

Aug 16, 2021

09:00AM EDT CohBar Appoints Carol Nast to Its Board of Directors GlobeNewswire Inc

Aug 13, 2021

05:37AM EDT The following are some of the stocks making big moves in Friday's pre-market trading (as of 5.30 A.M. EDT). RTTNews

Aug 12, 2021

05:46AM EDT Pre-market Movers: CNFR, XONE, XERS, OPEN, RTTNews

Aug 11, 2021

02:31PM EDT Mid-Afternoon Market Update: Dow Surges Over 200 Points; HyreCar Shares Plunge Benzinga

12:12PM EDT Mid-Day Market Update: Upstart Jumps Following Strong Q2 Results; ON24 Shares Slide Benzinga

10:08AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2021 Benzinga

07:23AM EDT WBB Securities Upgrades CohBar to Buy, Announces $5 Price Target Benzinga

Aug 10, 2021

04:25PM EDT CohBar Q2 EPS $(0.08) Misses $(0.06) Estimate Benzinga

04:04PM EDT CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today reported its financial results for the second quarter ended June 30, 2021. GlobeNewswire Inc

04:04PM EDT CohBar Reports Topline Results From Phase 1a/1b Study Of CB4211 For NASH, Obseity Benzinga

04:02PM EDT -- CB4211 was well-tolerated and appeared safe with no serious adverse events -- Robust reductions in ALT and AST -- Reduction in glucose and trend towards body weight reduction -- Company to host conference call and webcast at 5:00 p.m. ET GlobeNewswire Inc

04:05AM EDT Earnings Scheduled For August 10, 2021 Benzinga

Aug 4, 2021

04:05PM EDT CohBar to Announce 2021 Second Quarter Financial Results and GlobeNewswire Inc

Jul 14, 2021

11:42AM EDT CohBar Stock Slumps As Data From NASH, Obesity Candidate Delayed By Almost Two Months Benzinga

09:07AM EDT CohBar Says Process Of Data Entry And Final Validation In Phase 1a/1b Clinical Trial for CB4211 Is Ongoing, Expects To Release Topline Data Prior To Labor Day 2021 Benzinga

09:00AM EDT CohBar Provides Update on the Phase 1a/1b Clinical Trial for GlobeNewswire Inc

Jun 10, 2021

09:00AM EDT CohBar to Present at the BIO 2021 Digital Conference GlobeNewswire Inc

May 17, 2021

04:10PM EDT CohBar Q1 EPS $(0.07), Inline Benzinga

04:02PM EDT CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today reported its financial results for the first quarter ended March 31, 2021. GlobeNewswire Inc

04:10AM EDT Earnings Scheduled For May 17, 2021 Benzinga

May 3, 2021

09:00AM EDT CohBar to Announce 2021 First Quarter Financial Results and GlobeNewswire Inc

Apr 27, 2021

08:34AM EDT Cohbar Announces Appointment Of Joseph J. Sarret, As CEO And Director, Effective May 3, 2021 Benzinga

08:30AM EDT CohBar Appoints Joseph J. Sarret, M.D., J.D. as Chief Executive GlobeNewswire Inc

Apr 23, 2021

12:03PM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 23, 2021 Benzinga

09:01AM EDT Maxim Group Initiates Coverage On CohBar with Buy Rating, Announces Price Target of $3 Benzinga

Apr 21, 2021

09:02AM EDT CohBar Says Completes Last Subject Visit In Phase 1b Clinical Trial For CB4211 Under Development For NASH And Obesity Benzinga

09:00AM EDT CohBar Completes Last Subject Visit in the Phase 1b Clinical Trial GlobeNewswire Inc

Apr 14, 2021

09:00AM EDT CohBar to Present at the Mitochondria-Targeted Drug Development Summit GlobeNewswire Inc

Mar 30, 2021

04:02PM EDT CohBar Q4 EPS $(0.08) Misses $(0.06) Estimate Benzinga

04:02PM EDT CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today reported its financial results for the fourth quarter ended December 31, 2020. GlobeNewswire Inc

04:04AM EDT Earnings Scheduled For March 30, 2021 Benzinga

Mar 29, 2021

09:13AM EDT CohBar Completes Enrollment In Phase 1b Clinical Trial For CB4211 RTTNews

09:01AM EDT CohBar Says Completes Enrollment In Phase 1b Clinical Trial For CB4211 Under Development For NASH, Obesity Benzinga

09:00AM EDT CohBar Completes Enrollment in the Phase 1b Clinical Trial for GlobeNewswire Inc

Mar 16, 2021

04:05PM EDT CohBar to Announce 2020 Fourth Quarter Financial Results and GlobeNewswire Inc

09:06AM EDT CohBar Says Nominates CB5138 Analog As Lead Clinical Candidate For Idopathic Pulmonary FIbrosis, Other Fibrotic Diseases Benzinga

09:00AM EDT CohBar Nominates CB5138 Analog as Lead Clinical Candidate for GlobeNewswire Inc

Mar 15, 2021

11:09AM EDT Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2021 Benzinga

10:39AM EDT Aegis Capital Initiates Coverage On CohBar with Buy Rating, Announces Price Target of $6 Benzinga

Mar 12, 2021

09:00AM EST CohBar to Participate in M Vest LLC and Maxim Group GlobeNewswire Inc

Mar 2, 2021

09:00AM EST CohBar to Present at the 33rd Annual ROTH Conference GlobeNewswire Inc

Feb 25, 2021

09:00AM EST CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company overview at the H.C. Wainwright Global Life Sciences Conference, being held virtually March 9 10, 2021. GlobeNewswire Inc

Feb 9, 2021

09:00AM EST CohBar to Present at the BIO CEO & Investor Digital Conference GlobeNewswire Inc

Jan 20, 2021

09:00AM EST CohBar to Present at the 3rd Annual Longevity Therapeutics Conference GlobeNewswire Inc

Jan 11, 2021

09:14AM EST CohBar Signs Non-Clinical Evaluation Agreement With NIAID To Evaluate Potential Of CB5064 Analogs RTTNews

09:04AM EST CohBar Announces Preclinical Collaboration With NIAID To Evaluate Potential Of CB5064 Analogs For Treatment Of COVID-19 ARDS Benzinga

09:01AM EST CohBar Announces Preclinical Collaboration with NIAID to Evaluate GlobeNewswire Inc

Dec 17, 2020

10:17AM EST Benzinga's Top Upgrades, Downgrades For December 17, 2020 Benzinga

06:07AM EST Chardan Capital Initiates Coverage On CohBar with Buy Rating, Announces Price Target of $3 Benzinga

Dec 9, 2020

09:07AM EST CohBar Announces Preclinical Data 'Confirming' Efficacy Of Novel Apelin Agonists In Acute Respiratory Distress Syndrome Model Benzinga

09:00AM EST CohBar Confirms Efficacy of Novel Apelin Agonists in Acute GlobeNewswire Inc

Nov 19, 2020

09:00AM EST CohBar to Present at the Piper Sandler 32nd Annual Healthcare GlobeNewswire Inc

Nov 16, 2020

04:06PM EST CohBar Q3 EPS $(0.06) Beats $(0.07) Estimate Benzinga

04:01PM EST CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today reported its financial results for the third quarter ended September 30, 2020. GlobeNewswire Inc

04:26AM EST Earnings Scheduled For November 16, 2020 Benzinga

Nov 2, 2020

09:00AM EST CohBar to Announce 2020 Third Quarter Financial Results and GlobeNewswire Inc

Oct 27, 2020

09:09AM EDT CohBar To Participate At ROTH Capital COVID-19 Therapeutics In Development Event Oct. 28 Benzinga

09:00AM EDT CohBar to Participate at ROTH Capital COVID-19 Therapeutics in GlobeNewswire Inc

Oct 26, 2020

09:04AM EDT CohBar Antifibrotic Peptide In Combination With Nintedanib Shows Enhanced Effects In An Idiopathic Pulmonary Fibrosis Model Benzinga

09:00AM EDT CohBar Antifibrotic Peptide in Combination with Nintedanib Shows GlobeNewswire Inc

Oct 15, 2020

04:05PM EDT CohBar to Present at the BIO-Europe Conference GlobeNewswire Inc

10:11AM EDT WBB Securities Initiates Coverage On CohBar with Speculative Buy Rating, Announces Price Target of $4.5 Benzinga

Oct 8, 2020

09:00AM EDT CohBars CEO to Participate on the Emerging GlobeNewswire Inc

Oct 5, 2020

09:00AM EDT CohBar to Present at the BIO Investor Forum GlobeNewswire Inc

Sep 29, 2020

04:05PM EDT CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company update at the H.C. Wainwright 4th Annual NASH Investor Conference, being held virtually on October 5, 2020. GlobeNewswire Inc

Sep 17, 2020

10:37AM EDT Roth Capital Initiates Coverage On CohBar with Buy Rating, Announces Price Target of $8 Benzinga

Sep 10, 2020

04:05PM EDT CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company update at the Oppenheimer Fall Healthcare, Life Sciences, & MedTech Summit, being held virtually on September 21-23, 2020. GlobeNewswire Inc

Sep 4, 2020

11:25AM EDT Insider Buys CohBar's Stock Benzinga

Sep 3, 2020

08:45AM EDT CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company update at the H.C. Wainwright Annual Global Investment Conference, being held virtually on September 14-16, 2020. GlobeNewswire Inc

Aug 28, 2020

04:05PM EDT CohBar Announces Closing of Public Offering of Common Stock and GlobeNewswire Inc

Aug 26, 2020

02:31PM EDT Mid-Afternoon Market Update: Dow Rises 90 Points; Salesforce.com Shares Surge On Upbeat Q2 Results Benzinga

12:22PM EDT Mid-Day Market Update: Nasdaq Jumps 150 Points; Anaplan Shares Gain Following Q2 Results Benzinga

08:31AM EDT CohBar Prices 12.3M Unit Offering At $1.22/Unit Benzinga

08:30AM EDT CohBar Announces Pricing of $15.0 Million Public Offering of GlobeNewswire Inc

Aug 25, 2020

04:55PM EDT CohBar Announces Proposed Public Offering of Common Stock and Warrants; No Terms Disclosed Benzinga

04:55PM EDT CohBar Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire Inc

Aug 24, 2020

04:16PM EDT Cohbar Inc Files For Mixed Shelf Of Up To $100M Benzinga

09:08AM EDT CohBar Announces First Subjects Dosed In Its Phase 1b Clinical Trial For CB4211 Under Development For NASH And Obesity RTTNews

09:00AM EDT CohBar Announces First Subjects Dosed in its Phase 1b Clinical GlobeNewswire Inc

Aug 13, 2020

04:10PM EDT CohBar Q2 EPS $(0.09) Down From $(0.07) YoY Benzinga

04:03PM EDT New positive preliminary preclinical results in ARDS modelCompany to host conference call and webcast at 5:00 p.m. ET GlobeNewswire Inc

04:03AM EDT Earnings Scheduled For August 13, 2020 Benzinga

Aug 5, 2020

09:00AM EDT CohBar Presents New Antifibrotic Data at the American Thoracic GlobeNewswire Inc

Jul 30, 2020

09:00AM EDT CohBar to Announce 2020 Second Quarter Financial Results and GlobeNewswire Inc

Share